Justin Bowers

Puneet Souda

Daniel Arias

Matthew Hewitt

Paul Knight

Rachel Vatnsdal Olson

Subhalaxmi Nambi

Conor Noel McNamara

Daniel Leonard

Douglas Schenkel

Jacob Johnson

Matthew Larew

Matthew Stanton

Brendan Smith

Dan Arias

Doug Schenkel

Matt Larew

Rachel Vatnsdal

Salem Salem

Subbu Nambi

- Repligen reported **mid-teens (15%)** topline growth excluding COVID for the first half of fiscal year 2025, with **20%** growth including COVID, and projects **$725 million** in revenue for 2025, up from **$634 million** in 2024.  **[730272_2157086_1]** **[730272_2157086_3]** 
- The company observed a strong industry recovery in the first half of 2025, with order intake increasing by **more than 20%** at both biopharma and CDMO segments.  **[730272_2157086_3]**  Repligen aims to grow **5 points faster** than the overall bioprocessing market's expected 8-12% growth rate.  **[730272_2157086_9]** 
- Repligen maintains a highly diversified portfolio and customer base, with **80%** of its offerings having no direct competitors.  **[730272_2157086_1]**  Its largest customer accounted for only **6%** of sales in 2024, a significant reduction from **81%** with top ten customers a decade ago.  **[730272_2157086_2]** 
- With **$700 million** in cash, Repligen is open to M&A opportunities that bring differentiating technologies, particularly to address product gaps in bioreactors, cell culture media, and virus filtration, although organic growth is expected to double the company's size in the next five years.

Repligen Highlights Strong Growth and Diversified Strategy at Global Healthcare Conference

REPLIGEN (RGEN)